MBX Biosciences, Inc. Common Stock MBX · Stock Open MBX Biosciences, Inc. Common Stock in new tab
Analyst price targets
Recent rating changes, newest first
MBX Biosciences, Inc. Common Stock Analysis (MBX)
Is MBX Biosciences, Inc. Common Stock a good investment? MBX Biosciences, Inc. Common Stock (MBX) is currently trading at 52.48 USD. Market analysts have a consensus price target of 95.70 USD. This suggests a potential upside from current levels.
Earnings Schedule: MBX Biosciences, Inc. Common Stock is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -3.98.
Investor FAQ
Does MBX Biosciences, Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is MBX Biosciences, Inc. Common Stock?
MBX Biosciences, Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -2.37.
Company Profile
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Community Discussion